A real world UK and Ireland web based biomarker audit showed that HER2 1+ tumours accounted for 32.2% of all breast cancers, and the HER2 equivocal (2+) category for 12.9%, with 72.1% of the latter FISH non-amplified. This evidence concerns the gene ERBB2 and neoplasm.